
Validea's P/B Growth Investor model, based on Partha Mohanram's academic strategy for identifying high-performing low book-to-market growth stocks, rates Thermo Fisher Scientific (TMO) at 77%. While this score is just shy of the 80% threshold for 'some interest,' TMO demonstrates strong fundamental performance in areas like return on assets and cash flow, though it shows weaknesses in advertising and R&D relative to assets. The analysis highlights TMO's alignment with a growth model designed to identify market outperformers.
Thermo Fisher Scientific Inc. (TMO) receives a moderately positive evaluation from Validea's P/B Growth Investor model, scoring 77% based on the academic strategy of Partha Mohanram. This model specifically targets low book-to-market stocks with indicators of sustained growth. While the 77% score is just shy of the 80% threshold that typically indicates model interest, TMO demonstrates significant fundamental strengths. The company passed critical tests for its book-to-market ratio, return on assets (ROA), cash flow from operations to assets, and stability in both ROA and sales variance. These passes suggest strong profitability, efficient cash generation, and consistent operational performance. However, the analysis also flags weaknesses, as TMO failed the model's criteria for advertising-to-assets and research and development-to-assets ratios, indicating that its spending in these key growth-driving areas may be suboptimal relative to its asset base according to this specific framework.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately positive
Sentiment Score
0.40
Ticker Sentiment